Epidermal Growth Factor Receptor (EGFR) is a pivotal transmembrane receptor governing cancer cell signaling, represents an attractive molecular target for cutting-edge precision therapeutics.104 The innovative development of EGFR-targeting PDCs is strategically designed to leverage the overexpression of the EGFR in diverse cancer types. The gene discussed is NRP1; the disease is cancer.